在患有刺激性肠综合征的患者中,低FODMAP饮食后循环GLP-1的增加
Umael Khan1, Ingeborg Brønstad1,2, Eline Margrete Randulff Hillestad3,4
1Section of Gastroenterology, Department of Medicine, Haukeland University Hospital, Bergen, Norway.
Frontiers in nutrition
|August 29, 2025
概括
低FODMAP饮食显著改善了IBS症状,并增加了患有刺激性肠综合征 (IBS) 的患者的葡萄糖类-1 (GLP-1) 水平. 通过影响肠道激素调节, 这种饮食干预显示出治疗IBS的潜力.
科学领域:
- 胃肠病学
- 内分泌学
- 人类营养
背景情况:
- 可发酵的寡糖,分糖,单糖和多 (FODMAP) 和类似葡萄糖的-1 (GLP-1) 独立地与刺激性肠道综合征 (IBS) 的病理生理学有关.
- 对低FODMAP饮食对IBS患者循环GLP-1水平的影响的研究有限.
研究的目的:
- 研究12周低FODMAP饮食对诊断为IBS的患者血GLP-1水平的影响.
- 评估饮食干预后IBS症状严重程度和体重的变化.
主要方法:
- 一组30名IBS患者 (腹或混合型) 参与了为期12周的低FODMAP饮食.
- 测量包括血GLP-1水平,IBS严重性评分系统 (IBS-SSS),体重和FODMAP摄入量,评估是在干预前和后进行的.
主要成果:
- 低FODMAP饮食导致IBS-SSS平均值和体重显著降低 (p < 0. 01).
- 在12周的饮食干预后,血GLP-1水平显著增加 (p = 0. 027).
结论:
- 12周低FODMAP饮食可能会提高IBS患者的血GLP-1水平.
- 导致GLP-1增加的具体机制需要进一步研究.
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
413
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
413
Drugs for Treatment of Constipation-Predominant IBS
326
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
326
Irritable Bowel Syndrome III: Medical and Nursing Management
294
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
294
Drugs for Treatment of Diarrhea-Predominant IBS
292
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
292
Irritable Bowel Syndrome I: Introduction
369
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
369
Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416


